Jump to ContentJump to Main Navigation
Show Summary Details

Romanian Journal of Internal Medicine

4 Issues per year

Open Access
Online
ISSN
2501-062X
See all formats and pricing

VEGF expression in pancreatic cancer and other malignancies: a review of the literature

M.I. Costache
  • Corresponding author
  • Gastroenterology Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Romania
  • Radiology Department, University Hospital, Craiova, Romania
  • Email:
/ Mihai Ioana
  • Gastroenterology Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Romania
  • Nijmegen Institute for Infection, Inflammation and Immunity (N4i), Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
/ Sevastiţa Iordache
  • Gastroenterology Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Romania
/ D. Ene
  • “Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania
  • Surgery I Department, Floreasca Hospital, Bucharest, Romania
/ Cornelia Alexandra Costache
  • Neurology Department, Neuropsychiatry Hospital, Craiova, Romania
/ A. Săftoiu
  • Gastroenterology Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy Craiova, Romania
  • Gastrointestinal Unit, Copenhagen University Hospital Herlev, Denmark
Published Online: 2015-10-14 | DOI: https://doi.org/10.1515/rjim-2015-0027

Abstract

Angiogenesis is a crucial event for tumor growth and it is regulated predominantly by several different growth factors. Vascular endothelial growth factor protein family (VEGF) and its receptors are probably the most important tissue factors responsible for angioblast differentiation and tube formation. VEGF protein family currently comprises several members: VEGF (or VEGF-A), VEGF-B, VEGF-C and VEGF-D, VEGF-F, placental growth factor (PlGF), and their receptors VEGFR-1, VEGFR-2 and VEGFR-3. VEGF is a key angiogenic growth factor and its level of expression is a critical marker for detection of the angiogenic diseases. The potent role of VEGF in tumor angiogenesis has been widely described in the past decade, being expressed in most types of nondigestive and digestive cancers. VEGF family members play an important role in the development of pancreatic cancer (especially VEGF-A, VEGF-C, VEGF-D, VEGFR-1 and VEGFR-2). VEGF-A is the most specific and prominent angiogenic factor among all family members and VEGFR-2 is the most important receptor in evaluating the angiogenesis in pancreatic cancer. Thus, VEGF overexpression may be considered as a diagnostic marker and as a poor prognostic factor of the disease.

Angiogeneza este un eveniment crucial în creşterea şi dezvoltarea tumorală şi este controlată de o serie de factori de creştere. VEGF (factorul de creştere a endoteliului vascular) este, probabil, cel mai important factor tisular, implicat în diferenţierea angioblastelor şi în formarea reţelelor vasculare. Familia proteinei VEGF cuprinde în prezent mai mulţi membri: VEGF (sau VEGF-A), VEGF-B, VEGF-C şi VEGF-D, VEGF-F, factor de creştere placentar (PlGF) şi receptorii lor VEGFR-1, VEGFR-2 şi VEGFR-3. VEGF este un factor de creştere cheie, iar expresia sa este un marker critic pentru aprecierea bolilor angiogenice. Rolul decisiv al VEGF în angiogeneza tumorală a fost descris pe larg în ultimul deceniu, acesta fiind exprimat în majoritatea tipurilor de cancere non-digestive şi digestive. Membrii familiei VEGF joacă un rol esenţial în dezvoltarea cancerului pancreatic (în special VEGF-A, VEGF-C, VEGF-D, VEGFR-1 şi VEGFR-2). Dintre aceştia, nivelurile tisulare ale VEGF-A şi ale VEGFR-2 sunt cele mai specifice şi mai evidente în ceea ce priveşte utilitatea în evaluarea angiogenezei în cancerul pancreatic. Expresia genetică crescută a VEGF poate fi, astfel, considerată un important marker diagnostic dar şi un indice de prognostic nefavorabil al patologiei neoplazice pancreatice.

Keywords: Angiogenesis; VEGF; pancreatic cancer

REFERENCES

  • 1. HOEBEN A., LANDUYT B., HIGHLEY M.S., WILDIERS H., VAN OOSTEROM A.T., DE BRUIJN E.A. Vascular endothelial growth factor and angiogenesis. Pharmacol Rev. 2004; 56(4):549-580. [Crossref]

  • 2. CRIVELLATO E.The role of angiogenic growth factors in organogenesis. Int J Dev Biol. 2011; 55(4-5):365-75. [Crossref]

  • 3. GERHARDT H.. VEGF and endothelial guidance in angiogenic sprouting. Organogenesis. 2008; 4: 241-246. [Crossref]

  • 4. TAKAHASHI H., SHIBUYA M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond). 2005 Sep; 109(3):227-41. [Crossref]

  • 5. TISCHER E., GOSPODAROWICZ D., MITCHELL R., SILVA M., SCHILLING J., LAU K., CRISP T., FIDDES J.C., ABRAHAM J.A. Vascular endothelial growth factor: a new member of the platelet-derived growth factor gene family. Biochem Biophys Res Commun. 1989 Dec 29; 165(3):1198-1206. [Crossref]

  • 6. TAMMELA T., ENHOLM B., ALITALO K. AND PAAVONEN K. The biology of vascular endothelial growth factors. Cardiovas Res. 2005; 65: 550-563. [Crossref]

  • 7. DELGHANIAN F., HOJATI Z., KAY M. New insights into VEGF-A alternative splicing: Key regulatory switching in pathological process. Avicenna J Med Biotechnol. 2014 Oct; 6(4):192-9.

  • 8. GIACCA M. Non-redundant functions of the protein isoforms arising from alternative splicing of the VEGF-A pre-mRNA. Transcription 2010; 1(3):149-153. [Crossref]

  • 9. NEUFELD G., COHEN T., GENGRINOVITCH S., AND POLTORAK Z.Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999; 13:9-22.

  • 10. POLTORAK Z., COHEN T., SIVAN R., KANDELIS Y., SPIRA G., VLODAVSKY I., KESHET E., AND NEUFELD G. VEGF145, a secreted vascular endothelial growth factor isoform that binds to extracellular matrix. J Biol Chem 1997; 272:7151-7158.

  • 11. LEUNG D.W., CACHIANES G., KUANGW. J., GOEDDEL D. V. and FERRARA N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246, 1306-1309.

  • 12. KECK P. J., HAUSER S. D., KRIVI G. ET AL. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science. 1989; 246, 1309-1312.

  • 13. CONNOLLY, D. T., HEUVELMAN, D. M., NELSON, R. et al. Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J. Clin. Invest. 1989; 84, 1470-1478.

  • 14. FERRARA N. AND HENZEL W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989; 161, 851-858.

  • 15. KAJDANIUK D., MAREK B., BORGIEL-MAREK H., KOS-KUDLA B. Vascular endothelial growth factor (VEGF) part 1: in physiology and pathophysiology. Endokrynol Pol 2011; 62(5):444-455.

  • 16. OLOFSSON, B., JELTSCH, M., ERIKSSON, U. AND ALITALO, K. Current biology of VEGF-B and VEGF-C. Curr. Opin. Biotechnol. 1999; 10, 528-535.

  • 17. ORTEGA N., HUTCHINGS H., AND PLOUET J. Signal relays in the VEGF system. Front Biosci 1999; 4:141-152.

  • 18. WALTENBERGER J, CLAESSON-WELSH L, SIEGBAHN A, SHIBUYA M, and HELDIN CH Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 1994; 269:26988-26995.

  • 19. NAGY J. A., VASILE E., FENG D. et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 2002;196, 1497-1506.

  • 20. ACHEN M.G., JELTSCH M., KUKK E., MAKINEN T., VITALI A., WILKS A.F., ALITALO K., AND STACKER S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc NatlAcad Sci USA. 1999;95:548–553

  • 21. ZARKADA G., HEINOLAINEN K., MAKINEN T., KUBOTA Y., ALITALO K. VEGFR3 does not sustain retinal angiogenesis without VEGFR2. Proc Natl Acad Sci U S A. 2015 Jan 20; 112(3):761-6. [Crossref]

  • 22. FUKUMURA, D., XAVIER, R., SUGIURA, T. et al. Tumor induction of VEGF promoter activity in stromal cells. Cell. 1998; 94, 715-725.

  • 23. ZANG J., LI C., ZHAO L.N., SHI M., ZHOU Y.C., WANG J.H., LI X. Prognostic value of vascular endothelial growth factor in patients with head and neck cancer: A meta-analysis. Head Neck. 2013 Oct; 35(10):1507-14.

  • 24. ANDISHEH-TADBIR A., HAMZAVI M., REZVANI G., ASHRAF M.J., FATTAHI M.J., KHADEMI B., KAMALI F. Tissue expression, serum and salivary levels of vascular endothelial growth factor in patients with HNSCC. Braz J Otorhinolaryngol. 2014 Nov-Dec; 80(6):503-7.

  • 25. LUO H., LI J., YANG T., WANG J. Expression and significance of VEGF-C and VEGF-D in differentiated thyroid carcinoma. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2009 Jun; 23(12):531-4.

  • 26. LIU S.G., YUAN S.H., WU H.Y., LIU J., HUANG C.S. The Clinical Research of Serum VEGF, TGF-β1, and Endostatin in Non-small Cell Lung Cancer. Cell Biochem Biophys. 2014 Dec 30. [Epub ahead of print]

  • 27. FU Z.Z., SUN X.D., LI P., ZHANG Z., LI G.Z., GU T., SHAO S.S. Relationship between serum VEGF level and radiosensitivity of patients with nonsmall cell lung cancer among asians: a meta-analysis. DNA Cell Biol. 2014 Jul; 33(7):426-37. [Crossref]

  • 28. LIU G., XU S., JIAO F., REN T., LI Q. Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer. Tumour Biol. 2015 Mar; 36(3):2185-91 [Crossref]

  • 29. JIANG H., SHAO W., ZHAO W. VEGF-C in non-small cell lung cancer: meta-analysis. Clin Chim Acta. 2014 Jan 1; 427:94-9.

  • 30. SRABOVIC N., MUJAGIC Z., MUJANOVIC-MUSTEDANAGIC J., SOFTIC A., MUMINOVIC Z., RIFATBEGOVIC A., BEGIC L. Vascular endothelial growth factor receptor-1 expression in breast cancer and its correlation to vascular endothelial growth factor A.Int J Breast Cancer. 2013; 2013:746-749.

  • 31. ZHANG F., LI C., LIU H., WANG Y., CHEN Y., WU X. The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells. Tumour Biol. 2014 Dec; 35(12):12379-87. [Crossref]

  • 32. WANG H., HUANG X., ZHANG J., SHAO N., CHEN L.O., MA D., JI C. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer. Clin Chim Acta. 2014 Sep 25; 436:243-8.

  • 33. WIMBERGER P., CHEBOUTI I., KASIMIR-BAUER S., LACHMANN R., KUHLISCH E., KIMMIG R., SÜLEYMAN E., KUHLMANN J.D. Explorative investigation of vascular endothelial growth factor receptor expression in primary ovarian cancer and its clinical relevance. Gynecol Oncol. 2014 Jun; 133(3):467-72. [Crossref]

  • 34. MANDIC A., USAJ KNEZEVIC S., KAPICL IVKOVIC T. Tissue expression of VEGF in cervical intraepithelial neoplasia and cervical cancer. J BUON. 2014 Oct-Dec; 19(4):958-64.

  • 35. DEMEI M., XIANGXIN L., YONGPING X., YONGXIA Y., YUNHAI Y., LIN Z. Vascular endothelial growth factor C expression is closely correlated with lymph node recurrence and poor prognosis in patients with early stage cervical cancer. J Int Med Res. 2013 Oct; 41(5):1541-9. [Crossref]

  • 36. WANG J., TAYLOR A., SHOWEIL R., TRIVEDI P., HORIMOTO Y., BAGWAN I., EWINGTON L., LAM E.W., EL-BAHRAWY M.A. Expression profiling and significance of VEGF-A, VEGFR2, VEGFR3 and related proteins in endometrial carcinoma. Cytokine. 2014 Aug; 68(2):94-100. [Crossref]

  • 37. ZHUANG Y., WEI M. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis. Tumour Biol. 2014 Mar; 35(3):1745-9. [Crossref]

  • 38. YU X.W., WU T.Y., YI X., REN W.P., ZHOU Z.B., SUN Y.Q., ZHANG C.Q. Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis. Tumour Biol. 2014 Jan; 35(1):155-60. [Crossref]

  • 39. WOOLLARD D.J., OPESKIN K., COSO S., WU D., BALDWIN M.E., WILLIAMS E.D. Differential expression of VEGF ligands and receptors in prostate cancer.Prostate. 2013 May; 73(6):563-72. [Crossref]

  • 40. KOPPARAPU P.K., BOORJIAN S.A., ROBINSON B.D., DOWNES M., GUDAS L.J., MONGAN N.P., PERSSON J.L. Expression of VEGF and its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer.Anticancer Res. 2013 Jun; 33(6):2381-90.

  • 41. SUI L., LIU K., SHEN W., ZHANG L. Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis. Tumour Biol. 2014 Sep; 35(9):9085-93. [Crossref]

  • 42. KINOSHITA S., KASE S., ANDO R., DONG Z., FUKUHARA J., DONG Y., INAFUKU S., NODA K., NODA M., KANDA A., ISHIDA S. Expression of vascular endothelial growth factor in human ocular adnexal lymphoma. Invest Ophthalmol Vis Sci. 2014 May 13; 55(6):3461-7. [Crossref]

  • 43. ZHANG Y.H., DIAO L., YANG Q., DUO J., LIU Y.X., LIU S.X., YAO X. Expression of VEGFR-2 and VEGFR-3 in papillary renal cell carcinoma and their relationship with prognosis. Zhonghua Zhong Liu Za Zhi. 2010 Oct; 32(10):752-6.

  • 44. ZHAO S.F., YANG X.D., LU M.X., SUN G.W., WANG Y.X., ZHANG Y.K., PU Y.M., TANG E.Y. Prognostic significance of VEGF immunohistochemical expression in oral cancer: a meta-analysis of the literature. Tumour Biol. 2013 Oct; 34(5):3165-71. [Crossref]

  • 45. YANASE M., KATO K., YOSHIZAWA K., NOGUCHI N., KITAHARA H., NAKAMURA H. Prognostic value of vascular endothelial growth factors A and C in oral squamous cell carcinoma. J Oral Pathol Med. 2014 Aug; 43(7):514-20. [Crossref]

  • 46. AGGARWAL S., DEVARAJA K., SHARMA S.C., DAS S.N. Expression of vascular endothelial growth factor (VEGF) in patients with oral squamous cell carcinoma and its clinical significance. Clin Chim Acta. 2014 Sep 25; 436:35-40.

  • 47. LI J.D., LIANG R.Y., ZHAO Y.P., XU Y.L. Correlation analysis of VEGF and PTEN expression in gingival carcinoma. Shanghai Kou Qiang Yi Xue. 2014 Oct; 23(5):619-23.

  • 48. OMOTO I., MATSUMOTO M., OKUMURA H., UCHIKADO Y., SETOYAMA T., KITA Y., OWAKI T., KIJIMA Y., SHINCHI H., ISHIGAMI S., UENO S., NATSUGOE S. Expression of vascular endothelial growth factor-C and vascular endothelial growth factor receptor-3 in esophageal squamous cell carcinoma. Oncol Lett. 2014 Apr; 7(4):1027-1032.

  • 49. Yang Z, Wang YG, Su K. VEGF-C and VEGF-D expression and its correlation with lymph node metastasis in esophageal squamous cell cancer tissue. Asian Pac J Cancer Prev. 2015; 16(1):271-4.

  • 50. SU C.M., SU Y.H., CHIU C.F., CHANG Y.W., HONG CC, YU Y.H., HO Y.S., WU C.H., YEN C.S., SU J.L. Vascular endothelial growth factor-C upregulates cortactin and promotes metastasis of esophageal squamous cell carcinoma. Ann Surg Oncol. 2014 Dec; 21 Suppl 4:S767-75. [Crossref]

  • 51. XU X.L., LING Z.Q., CHEN W., XU Y.P., MAO W.M. The overexpression of VEGF in esophageal cancer is associated with a more advanced TMN stage: a meta-analysis. Cancer Biomark. 2013;13(2):105-13.

  • 52. HOU X., WEI J.C., FU J.H., WANG X., LUO R.Z., HE J.H., ZHANG L.J., LIN P., YANG H.X. Vascular Endothelial Growth Factor is a Useful Predictor of Postoperative Distant Metastasis and Survival Prognosis in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol. 2015 Feb 5 [Epub ahead of print].

  • 53. BLANK S., DECK C., DREIKHAUSEN L., WEICHERT W., GIESE N., FALK C., SCHMIDT T., OTT K. Angiogenic and growth factors in gastric cancer. J Surg Res. 2015 Apr; 194(2):420-9. [Crossref]

  • 54. WANG L., LI H.G., WEN J.M., PENG T.S., ZENG H., WANG L.Y. Expression of CD44v3, erythropoietin and VEGF-C in gastric adenocarcinomas: correlations with clinicopathological features. Tumori. 2014 May-Jun; 100(3):321-7.

  • 55. CAO W., FAN R., YANG W., WU Y. VEGF-C expression is associated with the poor survival in gastric cancer tissue. Tumour Biol. 2014 Apr; 35(4):3377-83. [Crossref]

  • 56. PENG L., ZHAN P., ZHOU Y., FANG W., ZHAO P., ZHENG Y., XU N. Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Mol Biol Rep. 2012 Oct; 39(10):9473-84. [Crossref]

  • 57. JI Y.N., WANG Q., LI Y., WANG Z. Prognostic value of vascular endothelial growth factor A expression in gastric cancer: a meta-analysis.Tumour Biol. 2014 Mar; 35(3):2787-93. [Crossref]

  • 58. WANG Y., YAO X., GE J., HU F., ZHAO Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorld Journal. 2014; 2014:102736.

  • 59. BEŞTAŞ R., KAPLAN M.A., IŞIKDOĞAN A. The correlation between serum VEGF levels and known prognostic risk factors in colorectal carcinoma.Hepatogastroenterology. 2014 Mar-Apr; 61(130):267-71.

  • 60. ARAÚJO R.F. JR, LIRA G.A., VILAÇA J.A., GUEDES H.G., LEITÃO M.C., LUCENA H.F., RAMOS C.C. Prognostic and diagnostic implications of MMP-2, MMP-9, and VEGF-α expressions in colorectal cancer. Pathol Res Pract. 2015 Jan; 211(1):71-7. [Crossref]

  • 61. GOOS J.A., DE CUBA E.M., COUPÉ V.M., DIOSDADO B., DELIS-VAN DIEMEN P.M., KARGA C., BELIËN J.A., MENKE-VAN DER HOUVEN VAN OORDT C.W., GELDOF A.A., MEIJER G.A., HOEKSTRA O.S., FIJNEMAN R.J.; THE DECODE PET GROUP. Glucose transporter 1 (SLC2A1) and vascular endothelial growth factor A (VEGFA) predict survival after resection of colorectal cancer liver metastasis. Ann Surg. 2015 Jan 5. [Epub ahead of print]

  • 62. XU C.J., XU F. MMP-11 and VEGF-C expression correlate with clinical features of colorectal adenocarcinoma. Int J Clin Exp Med. 2014 Sep 15; 7(9):2883-8.

  • 63. MARTINS S.F., GARCIA E.A., LUZ M.A., PARDAL F., RODRIGUES M., FILHO A.L. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer.Cancer Genomics Proteomics. 2013 Mar-Apr; 10(2):55-67.

  • 64. HSIEH M.C., HSU H.T., HSIAO P.C., YANG S.F., YEH C.B., BIEN M.Y., LIN C.H., CHIEN M.H. Role of VEGF-C gene polymorphisms in susceptibility to hepatocellular carcinoma and its pathological development.J Clin Lab Anal. 2014 May; 28(3):237-44. [Crossref]

  • 65. LETELIER P., GARCIA P., LEAL P., ILI C., BUCHEGGER K., RIQUELME I., SANDOVAL A., TAPIA O., ROA J.C. Immunohistochemical expression of vascular endothelial growth factor A in advanced gallbladder carcinoma. Appl Immunohistochem Mol Morphol. 2014 Aug; 22(7):530-6. [Crossref]

  • 66. LIN W., JIANG L., CHEN Y., SHE F., HAN S., ZHU J., ZHOU L., TANG N., WANG X., LI X. Vascular endothelial growth factor-D promotes growth, lymphangiogenesis and lymphatic metastasis in gallbladder cancer. Cancer Lett. 2012 Jan 28; 314(2):127-36. [Crossref]

  • 67. SIPOS B., KLAPPER W., KRUSE M.L., KALTHOFF H., KERJASCHKI D., KLÖPPEL G. Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am J Pathol. 2004 Oct; 165(4):1187-97. [Crossref]

  • 68. HANSEL D.E., RAHMAN A., HERMANS J., DE KRIJGER R.R., ASHFAQ R., YEO C.J., CAMERON J.L., MAITRA A. Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol. 2003 Jul; 16(7):652-9. [Crossref]

  • 69. REID M.D., CHOI H., BALCI S., AKKAS G., ADSAY V. Serous cystic neoplasms of the pancreas: clinicopathologic and molecular characteristics. Semin Diagn Pathol. 2014 Nov; 31(6):475-83. [Crossref]

  • 70. YIP-SCHNEIDER M.T., WU H., DUMAS R.P. HANCOCK B.A., AGARAM N., RADOVICH M., SCHMIDT C.M. Vascular endothelial growth factor, a novel and highly accurate pancreatic fluid biomarker for serous pancreatic cysts. J Am Coll Surg. 2014 Apr; 218(4):608-17.

  • 71. LISZKA Ł., PAJĄK J., GOŁKA D. Serous neoplasms of the pancreas share many, but not all aspects of their microvascular and angiogenic profile with low-grade clear cell renal cell carcinomas. Pathol Res Pract. 2014 Dec; 210(12):901-8. [Crossref]

  • 72. AI K.X., LU L.Y., HUANG X.Y., CHEN W., ZHANG H.Z. Prognostic significance of S100A4 and vascular endothelial growth factor expression in pancreatic cancer.World J Gastroenterol. 2008 Mar 28; 14(12):1931-5.

  • 73. VON MARSCHALL Z., CRAMER T., HÖCKER M., BURDE R., PLATH T., SCHIRNER M., HEIDENREICH R., BREIER G., RIECKEN E.O., WIEDENMANN B., ROSEWICZ S. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology. 2000 Nov; 119(5):1358-72.

  • 74. SEO Y., BABA H., FUKUDA T., TAKASHIMA M., SUGIMACHI K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer. 2000 May 15; 88(10):2239-45. [Crossref]

  • 75. LIANG Q.L., WANG B.R., CHEN G.Q., LI G.H., XU Y.Y. Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancerclinicopathologic parameters. Med Oncol. 2010 Dec; 27(4):1164-70. [Crossref]

  • 76. ZORGETTO V.A., SILVEIRA G.G., OLIVEIRA-COSTA J.P., SOAVE D.F., SOARES F.A., RIBEIRO-SILVA A. The relationship between lymphatic vascular density and vascular endothelial growth factor A (VEGF-A)expression with clinical-pathological features and survival in pancreatic adenocarcinomas. Diagn Pathol. 2013 Oct 18; 8:170. [Crossref]

  • 77. GEORGIADOU D., SERGENTANIS T.N., SAKELLARIOU S., FILIPPAKIS G.M., ZAGOURI F., VLACHODIMITROPOULOS D., PSALTOPOULOU T., LAZARIS A.C., PATSOURIS E., ZOGRAFOS G.C.VEGF and Id-1 in pancreatic adenocarcinoma: prognostic significance and impact on angiogenesis. Eur J Surg Oncol. 2014 Oct; 40(10):1331-7. [Crossref]

  • 78. SMITH R.A., TANG J., TUDUR-SMITH C., NEOPTOLEMOS J.P., GHANEH P. Meta-analysis of immunohistochemical prognostic markers in resected pancreatic cancer. Br J Cancer. 2011 Apr 26; 104(9):1440-51. [Crossref]

  • 79. PATSOURAS D., PAPAXOINIS K., KOSTAKIS A., SAFIOLEAS M.C., LAZARIS A.C., NICOLOPOULOU-STAMATI P. Fibroblast activation protein and its prognostic significance in correlation with vascular endothelial growth factor in pancreatic adenocarcinoma. Mol Med Rep. 2015 Jun; 11(6):4585-90

  • 80. SIPOS B., WEBER D., UNGEFROREN H., KALTHOFF H., ZÜHLSDORFF A., LUTHER C., TÖRÖK V., KLÖPPEL G. Vascular endothelial growth factor mediated angiogenic potential of pancreatic ductal carcinomas enhanced by hypoxia: an in vitro and in vivo study. Int J Cancer. 2002 Dec 20; 102(6):592-600. [Crossref]

  • 81. ANDREOZZI M., QUAGLIATA L., GSPONER J.R., RUIZ C., VUAROQUEAUX V., EPPENBERGER-CASTORI S., TORNILLO L., TERRACCIANO L.M. VEGFA gene locus analysis across 80 human tumour types reveals gene amplification in several neoplastic entities. Angiogenesis. 2014 Jul; 17(3):519-27. [Crossref]

  • 82. TANG R.F., WANG S.X., PENG L., WANG S.X., ZHANG M., LI Z.F., ZHANG Z.M., XIAO Y., ZHANG F.R. Expression of vascular endothelial growth factors A and C in human pancreatic cancer.World J Gastroenterol. 2006 Jan 14; 12(2):280-6. [Crossref]

  • 83. DOI Y., YASHIRO M., YAMADA N., AMANO R., NODA S., HIRAKAWA K. VEGF-A/VEGFR-2 signaling plays an important role for the motility of pancreas cancer cells. Ann Surg Oncol. 2012 Aug; 19(8):2733-43. [Crossref]

  • 84. DOI Y., YASHIRO M., YAMADA N., AMANO R., OHIRA G., KOMOTO M., NODA S., KASHIWAGI S., KATO Y., FUYUHIRO Y., HIRAKAWA K. Significance of phospho-vascular endothelial growth factor receptor-2 expression in pancreatic cancer. Cancer Sci. 2010 Jun; 101(6):1529-35. [Crossref]

  • 85. KNOLL M.R., RUDNITZKI D., STURM J., MANEGOLD B.C., POST S., JAEGER T.M. Correlation of postoperative survival and angiogenic growth factors in pancreatic carcinoma. Hepatogastroenterology. 2001 Jul-Aug; 48(40):1162-5.

  • 86. TANG R.F., ITAKURA J., AIKAWA T., MATSUDA K., FUJII H., KORC M., MATSUMOTO Y. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas. 2001 Apr; 22(3):285-92. [Crossref]

  • 87. SCHNEIDER M., BÜCHLER P., GIESE N., GIESE T., WILTING J., BÜCHLER M.W., FRIESS H. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol. 2006 Apr; 28(4):883-90.

  • 88. CHENG P., JIN G., HU X., SHI M., ZHANG Y., LIU R., ZHOU Y., SHAO C., ZHENG J., ZHU M. Analysis of tumor-induced lymphangiogenesis and lymphatic vessel invasion of pancreatic carcinoma in the peripheral nerve plexus. Cancer Sci. 2012 Oct; 103(10):1756-63. [Crossref]

  • 89. LI K., LI M.J., HE T., ZHENG Z., ZHENG X.L., QU B.H., WANG Y., DUAN X., ZHENG Y.J. Expression of vascular endothelial growth factor C in pancreatic cancer and its effect upon lymph node metastasis. Zhonghua Yi Xue Za Zhi. 2009 Sep 15; 89(34):2386-90.

  • 90. VON MARSCHALL Z., SCHOLZ A., STACKER S.A., ACHEN M.G., JACKSON D.G., ALVES F., SCHIRNER M., HABEREY M., THIERAUCH K.H., WIEDENMANN B., ROSEWICZ S. Vascular endothelial growth factor-D induces lymphangiogenesis and lymphatic metastasis in models of ductal pancreatic cancer. Int J Oncol. 2005 Sep; 27(3):669-79.

  • 91. KURAHARA H., TAKAO S., MAEMURA K., SHINCHI H., NATSUGOE S., AIKOU T. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis.Clin Cancer Res. 2004 Dec 15; 10(24):8413-20. [Crossref]

  • 92. WEY J.S., FAN F., GRAY M.J., BAUER T.W., MCCARTY M.F., SOMCIO R., LIU W., EVANS D.B., WU Y., HICKLIN D.J., ELLIS L.M. Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines.Cancer. 2005 Jul 15; 104(2):427-38. [Crossref]

  • 93. YANG A.D., CAMP E.R., FAN F., SHEN L., GRAY M.J., LIU W., SOMCIO R., BAUER T.W., WU Y., HICKLIN D.J., ELLIS L.M.. Vascular endothelial growth factor receptor-1 activation mediates epithelial to mesenchymal transition in human pancreatic carcinoma cells. Cancer Res. 2006 Jan 1; 66(1):46-51. [Crossref]

  • 94. CHUNG G.G., YOON H.H., ZERKOWSKI M.P., GHOSH S., THOMAS L., HARIGOPAL M., CHARETTE L.A., SALEM R.R., CAMP R.L., RIMM D.L., BURTNESS B.A. Vascular endothelial growth factor, FLT-1, and FLK-1 analysis in a pancreatic cancer tissue microarray.Cancer. 2006 Apr 15; 106(8):1677-84. [Crossref]

  • 95. ANGELESCU R., BURADA F., ANGELESCU C., GHEONEA D.I., IORDACHE S., MIXICH F., IOANA M., SĂFTOIU A. Expression of vascular endothelial growth factor and epidermal growth factor receptor in pancreatic ductal adenocarcinomas, neuroendocrine tumours and chronic pancreatitis. Endosc Ultrasound. 2013 Apr; 2(2):86-91.

About the article

Received: 2015-04-18

Published Online: 2015-10-14

Published in Print: 2015-09-01


Citation Information: Romanian Journal Of Internal Medicine, ISSN (Online) 1220-4749, DOI: https://doi.org/10.1515/rjim-2015-0027. Export Citation

© 2015 M.I. Costache et al., published by De Gruyter Open. This chapter is distributed under the terms of the Creative Commons Attribution 4.0 Public License. (CC BY 4.0)

Comments (0)

Please log in or register to comment.
Log in